GH Secretagogues
CJC-1295 (No DAC / Modified GRF 1-29)
← Back to Library
Limited / unverified FDA safety flag Limited / unverified GH Axis
Educational reference only. Read the full disclaimer.
The protocols below are not automatically an FDA-approved or clinically verified regimen unless
explicitly marked as label-verified or clinical-trial above.
Overview
Route(s): Subcutaneous
Typical vial sizes: 2, 5, 10 mg
Dosing window: Pre-Bed Fasted
Receptor / target: GHRH
Properties: GH Secretagogue
Pre-mixed: No
Unverified protocol notes
Standard Protocol
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-12 | 100mcg once daily | Administered right before bed. Must be fasted for 2+ hours. |
Unverified protocol note; not label dosing unless graded otherwise on this page.
Alternative Titration 1
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-2 | 100 mcg 1x Daily | At bedtime fasted. |
| Weeks 3-4 | 150 mcg 1x Daily | At bedtime fasted. |
| Weeks 5-6 | 200 mcg 1x Daily | At bedtime fasted. |
| Weeks 7-12 | 250-300 mcg 1x Daily | At bedtime fasted. |
Unverified alternative protocol; not an approved-label regimen unless graded otherwise on this page.
Alternative Titration 2 (Low-Dose / Anti-Aging)
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-4 | 100mcg 1x Daily | At bedtime fasted. |
| Weeks 5-12 | 150mcg 1x Daily | At bedtime fasted. |
Unverified alternative protocol; not an approved-label regimen unless graded otherwise on this page.
Alternative Titration 3 (2x/Day Protocol)
| Timeframe | Dose | Notes |
|---|---|---|
| Week 1 | 100 mcg 2x/day | AM/PM fasted. |
| Weeks 2-4 | 200 mcg 2x/day | AM/PM fasted. |
| Weeks 5-8 | 300 mcg 2x/day | AM/PM fasted. |
Unverified alternative protocol; not an approved-label regimen unless graded otherwise on this page.
Alternative Titration 4 (3x/Day Protocol)
| Timeframe | Dose | Notes |
|---|---|---|
| Days 1-3 | 150 mcg 3x/day | AM/PM fasted, MidDay post meal. |
| Days 4-7 | 200 mcg 3x/day | AM/PM fasted, MidDay post meal. |
| Weeks 2-3 | 300 mcg 3x/day | AM/PM fasted, MidDay post meal. |
| Weeks 4-6 | 400 mcg 3x/day | AM/PM fasted, MidDay post meal. |
| Weeks 7-12 | 500 mcg 3x/day | AM/PM fasted, MidDay post meal. |
Unverified alternative protocol; not an approved-label regimen unless graded otherwise on this page.
Protocol logic check
Protocol context: GH-axis protocols are not 'more is better.' The logic is pulse quality, recovery time, IGF-1/glucose monitoring, and avoiding receptor desensitization, edema, appetite spikes, numbness, or blood-pressure strain. Entry context: target (GHRH); route Subcutaneous; timing Pre-Bed Fasted. Limited-evidence dosing tables are hypotheses, not recommendations. FDA/safety flags lower confidence and raise the evidence bar for any claimed benefit. Compatibility is conditional: a reasonable solo compound can become inappropriate once a contraindicated partner is added. GH-axis stacking should be filtered for total IGF-1/glucose burden, not just expected synergy.
Independent evidence
Independent safety notes: FDA lists CJC-1295 among withdrawn nominated bulk substances with potential significant safety risks, limited clinical data, and serious adverse events reported.
Regulatory status: unapproved or compounded peptide with FDA safety risk flag
Storage
No independently verified storage guidance found. Treat any unverified storage claim as unverified, and see the general storage guidance in the FAQ.
Contraindications (limited evidence)
- Active cancer or history of malignancy: GH elevation accelerates cell proliferation; contraindicated in any hormone-sensitive or actively growing tumor. Limited / unverified
- High risk of tumor growth: subjects with pre-cancerous conditions, strong family history of growth-hormone sensitive cancers, or elevated cancer biomarkers. Limited / unverified
- Active acromegaly or other conditions involving excess endogenous GH or IGF-1. Limited / unverified
- Diabetic ketoacidosis: acute metabolic instability precludes GH-axis manipulation. Limited / unverified
- Uncontrolled diabetes mellitus or significant insulin resistance: IGF-1 elevation from GH stimulation worsens glucose metabolism. Limited / unverified
- Pregnancy: safety not established; GH axis stimulation during pregnancy is not advised. Limited / unverified
- Breastfeeding: safety not established. Limited / unverified
- Known hypersensitivity to CJC-1295 or any formulation excipients. Limited / unverified
- Concurrent use with CJC-1295 DAC, tesamorelin, sermorelin, or HGH 191aa: direct GHRH receptor competition or redundant GH axis overstimulation. Limited / unverified
- Concomitant glucocorticoid therapy at high doses: glucocorticoids blunt pituitary GH response and inhibit IGF-1 production. Limited / unverified
- Disruption of the hypothalamic-pituitary axis (e.g., pituitary adenoma, cranial radiation history): GHRH-R stimulation may be unpredictable. Limited / unverified
- Pediatric use in children with closed growth plates: inappropriate bone growth stimulation risk. Limited / unverified
Side effects (limited evidence)
- Head rush and transient facial flushing immediately following injection: caused by acute GH pulse-induced vasodilation; typically resolves within 15-30 minutes. Limited / unverified
- Water retention and mild peripheral edema: GH-mediated sodium and fluid retention; most pronounced in the first 2-4 weeks and in higher-dose protocols. Limited / unverified
- Mild fatigue or lethargy: transient, typically occurs within 30-60 minutes post-injection; associated with the acute GH pulse. Limited / unverified
- Headache: related to vasodilation from the GH pulse; common in the first 1-2 weeks; diminishes with continued use. Limited / unverified
- Dizziness or lightheadedness: transient; associated with acute GH-mediated vasodilation. Limited / unverified
- Tingling or numbness in hands and feet: paresthesia from GH-related fluid shifts; more common at higher doses. Limited / unverified
- Vivid dreams: GH elevation during the nocturnal sleep cycle intensifies REM-phase dream vividness. Limited / unverified
- Joint stiffness: GH-mediated fluid in periarticular tissue; common at higher dose levels. Limited / unverified
- Mild hypoglycemia: possible when combined with fasting and a GHRP; GH pulse temporarily shifts glucose partitioning toward fat oxidation. Limited / unverified
- Increased appetite: modest; GH elevation has mild orexigenic effects. Limited / unverified
- Mild transient blood pressure elevation: secondary to GH-induced sodium retention; generally within normal range. Limited / unverified
- Injection site irritation: redness, swelling, or discomfort at subcutaneous administration site. Limited / unverified
- Pituitary desensitization with continuous use beyond cycle length: GH response attenuates if 12-16 week cycle limit is exceeded without washout. Limited / unverified
- Blunted efficacy from insufficient fasting: eating carbs or fats within 2 hours of injection significantly reduces or eliminates the GH pulse; not a side effect per se but the primary compliance failure point. Limited / unverified
Compatibility
The relationships below come from the source site's internal engine and were not verified independently. Treat them as a starting point for a conversation with a clinician. They carry no safety guarantee.
Reported synergistic:
Reported contraindicated combinations: